Japanese Device Maker Nipro Estimates Further Growth For FY2009
This article was originally published in PharmAsia News
Japanese medical device maker Nipro's 2008 sales grew by 2.2 percent to ¥175.9 billion. The operating income increased by 8 percent to ¥14.7 billion and net profit increased by 1.7 percent to ¥4.5 billion. In the domestic market, Nipro's dialysis products, injection and intravenous injection products steadily expanded market shares. Its pharmaceutical business also contributed to growth, especially in oral tablets and dialysis medicines. For fiscal year 2009, Nipro estimates further expansion in its pharma business, due largely to growth in the generic drug market and increasing diagnostic procedure combined payment methods. Estimated 2009 sales are ¥180 billion, with ¥6 billion in net product for a 33.5 percent increase. (Click here for more - Japanese language
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.